Journal of Nuclear Medicine (J NUCL MED)

Publications in this journal

• Article: Recombinant Human TSH Versus Thyroid Hormone Withdrawal.

  Verburg FA, Dietlein M, Freudenberg L, Leboulleux S, Pitoia F, Reiners C, Stokkel M, Luster M
  Journal of Nuclear Medicine 09/2012;
• Article: MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy

  Sgouros
  Journal of Nuclear Medicine 01/2012;
• Article: Comparison of automatic segmentation methods on multicenter PET images for tumor volume definition

  Thomas de Brouwer, Bruno Vanderlinden, Thomas Guiot, Camilo Garcia, Patrick Flamen
  [show abstract] [hide abstract]
  ABSTRACT: Abstract Objectives: One of the challenges in image-guided radiation therapy has been the search for a robust and reproducible method of delineation of Gross tumor volume from PET imaging in order to reduce the margins of the field treatments. Several segmentation methods have been proposed. In this study, we compared some of those segmentation algorithms on phantom images obtained in different PET centres using local clinical acquisition/reconstruction protocols. Methods: The phantom defined in the IEC 61675-1 and NEMA NU2-2007 protocols was used. The phantom background was filled with 2.6 kBq/ml of 18F-FDG, which is close to background activity observed in clinical conditions. The spheres (10, 13, 17, 22, 28 and 37 mm of diameter) were filled with 3, 6 and 9 times the background activity. Acquisition and reconstruction settings were the ones used in clinical routine for whole body FDG PET-CT by each centre (10 centers, 6 different brand/model PET/CT cameras). The segmentation algorithms tested are of two types: thresholding methods (42 % of MAX, 50 % (MAX + BKG), Nestle, Biehl, Black, Jentzen) and variational methods (levelset, Geets). The segmentation algorithms have been implemented in a single dedicated software. To compare the methods, we calculated the root mean square (RMS) of the differences between theoretical and segmented diameters. This comparison was carried on in two steps: first we evaluated the effect of contrast at fixed spatial resolution (one center), then we assessed the effect of different resolutions with all centers and one contrast (contrast 9). Results: For a fixed resolution, the best algorithm is Jentzen with a RMS of 0.67 mm. For a fixed contrast, the best algorithm is Black with a RMS of 1.01 mm. Conclusions: The algorithms described by Black et al and Jentzen et al give excellent volume estimations for homogeneous spheres using local standard reconstructions from 10 Belgian PET/CT centers. These algorithms have yet to be tested on heterogeneous objects in simulated images and in vivo images
  Journal of Nuclear Medicine 01/2012; 53.
• Article: 99mTc-bone marrow-targeted liposomal carriers: Comparison between rat, mice, hamster, rabbit and rhesus monkey

  Keitaro Sou, Beth Goins, Babatunde O. Oyajobi, Bruno L. Travi, William T. Phillips
  Journal of Nuclear Medicine 06/2011; 52(Supplement 1):1615.
• Article: Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study.

  Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Mechtersheimer G, Schmitt T, Lehner B, Haberkorn U, Stroebel P, Kasper B
  Journal of Nuclear Medicine 04/2010;
• Article: MRI-based attenuation correction and quantification tools for combined MRI/PET

  Baowei Fei, Xiaofeng Yang, Jonathon Nye, Margie Jones, John Aarsvold, Nivedita Raghunath, Carolyn Meltzer, John, Votaw
  Journal of Nuclear Medicine 01/2010; 81.
• Article: Susan C. Weiss, BS, CNMT, 1944-2009.

  James Conway
  Journal of Nuclear Medicine 10/2009; 50(9):33N-4N.
• Article: MI grants fuel advances in molecular imaging research.

  Craig Levin
  Journal of Nuclear Medicine 10/2009; 50(9):37N.
• Source

  Available from: snmjournals.org

  Article: Embracing the challenges ahead--together.

  Michael Graham
  Journal of Nuclear Medicine 10/2009; 50(9):36N-7N.
• Article: Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.

  Susan E Buckley, Sarah J Chittenden, Frank H Saran, Simon T Meller, Glenn D Flux
  [show abstract] [hide abstract]
  ABSTRACT: The aims of this study were to examine the relationship between whole-body absorbed dose and hematologic toxicity and to assess the most accurate method of delivering a prescribed whole-body absorbed dose in (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for neuroblastoma. A total of 20 children (1-12 y), 5 adolescents (13-17 y), and 1 adult (20 y) with stage 3 or 4 neuroblastoma were treated to a prescribed whole-body absorbed dose, which in most cases was 2 Gy. Forty-eight administrations of (131)I-MIBG were given to the 26 patients, ranging in activity from 1,759 to 32,871 MBq. For 30 administrations, sufficient data were available to assess the effect of whole-body absorbed dose on hematologic toxicity. Comparisons were made between the accuracy with which a whole-body absorbed dose could be predicted using a pretherapy tracer study and the patient's most recent previous therapy. The whole-body absorbed dose that would have been delivered if the administered activity was fixed (7,400 MBq) or determined using a weight-based formula (444 MBq.kg(-1)) was also estimated. The mean whole-body absorbed dose for patients with grade 4 Common Terminology Criteria for Adverse Events (CTCAE) neutropenia after therapy was significantly higher than for those with grade 1 CTCAE neutropenia (1.63 vs. 0.90 Gy; P = 0.05). There was no correlation between administered activity and hematologic toxicity. Absorbed whole-body doses predicted from previous therapies were within +/-10% for 70% of the cases. Fixed-activity administrations gave the largest range in whole-body absorbed dose (0.30-3.11 Gy). The results indicate that even in a highly heterogeneous and heavily pretreated patient population, a whole-body absorbed dose can be prescribed accurately and is a more accurate predictor of hematologic toxicity than is administered activity. Therefore, a whole-body absorbed dose can be used to deliver accurate and reproducible (131)I-MIBG therapy on a patient-specific basis.
  Journal of Nuclear Medicine 10/2009; 50(9):1518-24.
• Article: Thomas receives loevinger-berman award.

  George Sgouros
  Journal of Nuclear Medicine 10/2009; 50(9):35N.
• Article: Novel Techniques for Imaging the Heart: Cardiac MR and CT.

  Aurelio Matamoros
  Journal of Nuclear Medicine 10/2009; 50(9):1559.
• Source

  Available from: snmjournals.org

  Article: Creating a new, smarter health care.

  Henry N Wagner
  Journal of Nuclear Medicine 10/2009; 50(9):14N-32N.
• Article: Advanced Imaging in Biology and Medicine: Technology, Software Environment, Applications.

  Aurelio Matamoros
  Journal of Nuclear Medicine 09/2009;